Lombard Medical, Inc (Nasdaq: EVAR), a medical device company focused on
Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA),
today announced that it completed its second round of U.S. sales hires
bringing the total number in the domestic sales force to 34.
The Company’s lead product Aorfix™ is the only AAA stent graft approved
by the FDA for treating patients with aortic aneurysm neck angulations
up to 90 degrees.
Simon Hubbert, CEO of Lombard Medical, said, “I am delighted to announce
this significant increase in the size of our U.S. sales and marketing
team. As outlined during our recent successful IPO, we are focused on
accelerating the commercialization of Aorfix in the U.S. We are
therefore pleased to have attracted some of the industry’s best and
brightest professionals - more than half of whom have previous
endovascular AAA experience - to help drive U.S. adoption of this
differentiated stent graft. Our strategy is to be the clinical partner
of choice with the physician when treating complex AAA disease by
training a sales force with ‘best in class’ knowledge and skills.”
“We will continue to invest in our physician and sales force training
and have developed leading-edge tools to facilitate case planning and
rapid learning,” said Michael Gioffredi, U.S. president North America
Commercial Operations. “We believe that we are the first EVAR company to
provide each sales representative with a computer simulation tool,
providing real-time procedure simulation and training on the broad range
of clinical scenarios supported by our FDA approval.”
Lombard will continue to build out the U.S. sales team as it expands its
commercial footprint into the single largest endovascular stent graft
market. The Company anticipates a U.S. commercial organization of
approximately 50 individuals by mid-2015.
About Lombard Medical, Inc.
Lombard Medical, Inc. is a medical device company focused on device
solutions for the $1.4 billion per annum abdominal aortic aneurysm
repair market. The Company’s lead product, Aorfix™, is an endovascular
stent graft which has been specifically designed to solve the problems
that exist in treating complex tortuous anatomy, which is often present
in advanced AAA disease. Lombard Medical, Inc. is based in Oxfordshire,
England with U.S. commercial headquarters in Irvine, CA and is
registered in the Cayman Islands.
FORWARD-LOOKING STATEMENTS:
This announcement may contain forward-looking statements that reflect
the Company’s current expectations regarding future events, including
the commercialization and additional regulatory clearances of the
Company’s products, the Company's liquidity and results of operations,
as well as future capital raising activities. Forward-looking statements
involve risks and uncertainties. Actual events could differ materially
from those projected herein and depend on a number of factors, including
the success of the Company’s research and development and
commercialization strategies, the uncertainties related to the
regulatory process and the acceptance of the Company’s products by
hospitals and other medical professionals and the risks, uncertainties
and other factors described under the heading “Risk Factors” in the
Company’s prospectus filed with the Securities and Exchange Commission
dated April 25, 2014. The Company undertakes no obligation to update
these statements in the future.
Copyright Business Wire 2014